|
Post by akemp3000 on Jul 15, 2018 18:58:41 GMT -5
Some think it may take years before Dr. Kendall will be successful obtaining the Standard of Care designation due to lengthy procedures for change and a requirement for a larger trial. I disagree because the latest scientific data shows serious superiority with Afrezza offering an alternative to current standards of care with…say 30 percent less hypos. Inaction will be publicly exposed.
How long before we see the first law firm commercial asking, "Has anyone you know been hospitalized or died from complications with hypoglycemia while taking Novolog (or insert other)? If so, they may be entitled to compensation!" I’m not predicting this will happen soon, just saying it’s one of many angles that might appear. IMO, the industry cannot wait years to act because of the scientific data that Dr. Kendall is now sharing with thought leaders in the industry.
|
|